Get the Stockscreener App
0.7775
26.17%
0.1752
Briacell Therapeutics Corp stock is traded at $0.7775, with a volume of 2.18M.
It is up +26.17% in the last 24 hours and down -4.56% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.6023
Open:
$0.6185
24h Volume:
2.18M
Relative Volume:
0.45
Market Cap:
$21.75M
Revenue:
-
Net Income/Loss:
$-6.00M
P/E Ratio:
-5.8109
EPS:
-0.1338
Net Cash Flow:
$-31.01M
1W Performance:
+27.71%
1M Performance:
-4.56%
6M Performance:
-49.00%
1Y Performance:
-82.92%
1-Day Range:
$0.61
$0.8212
1-Week Range:
$0.555
$0.8212
52-Week Range:
$0.4641
$5.97
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BCTX | 0.7741 | 21.75M | 0 | -6.00M | -31.01M | -0.1338 |
| VRTX | 449.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.31 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.97 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - GlobeNewswire
BriaCell Launches Phase 1/2 Trial of Next-Gen Breast Cancer Immunotherapy | BCTX Stock News - StockTitan
Closing Bell: Briacell Therapeutics Corp Down On Monday (BCT) - Barchart
BriaCell Showcases Robust Anti-Cancer Activity of - GlobeNewswire
BriaCell's Next-Gen Cancer Immunotherapies Show Breakthrough Results in Preclinical Data | BCTX Stock News - StockTitan
BriaCell Overall Survival Data Selected for Spotlight - GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 - StockTitan
BriaCell Therapeutics Faces Uncertain Financial Future - TipRanks
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2024 - Marketscreener.com
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha
BriaCell reports survival data from Phase 2 study | 2024-10-22 | Investing News - Stockhouse Publishing
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data - GlobeNewswire
You might want to take a look at BriaCell Therapeutics Corp (BCTX) now - SETE News
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study - GlobeNewswire
BriaCell Therapeutics advances Phase 3 MBC clinical study | 2024-10-15 | Investing News - Stockhouse Publishing
BCTX’s 52-Week Rollercoaster: From $0.46 to $5.97 – What’s Next for Investors? - The InvestChronicle
BriaCell stock gains after trial update (NASDAQ:BCTX) - Seeking Alpha
Extendicare Inc. - Baystreet.ca
BriaCell Therapeutics Corp. - Baystreet.ca
Analyzing BriaCell Therapeutics Corp (BCTX) After Recent Trading Activity - Knox Daily
BriaCell Therapeutics Corp (BCTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Deeper Dive: Understanding BriaCell Therapeutics Corp (BCTX) Through its Various Ratios - The Dwinnex
Clean Harbors (CLH-N) QuotePress Release - The Globe and Mail
BriaCell Therapeutics Corp: Navigating a Turbulent Year, Up -82.63% from 52-Week Low - The InvestChronicle
Financial Metrics Check: BriaCell Therapeutics Corp (BCTX)’s Ratios for Trailing Twelve Months - The Dwinnex
It is Poised to be a Bull Market for BriaCell Therapeutics Corp (BCTX) - SETE News
A Guide To The Risks Of Investing In BriaCell Therapeutics Corp (BCTX) - Knox Daily
BMO MSCI ACWI Paris Aligned Climate Equi (ZGRN-T) QuotePress Release - The Globe and Mail
BriaCell Therapeutics’ (BCTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Briacell stock Buy rating reaffirmed with clinical success in metastatic breast cancer trial - Investing.com
BriaCell Therapeutics Announces Closing of $5 Million Offering - GlobeNewswire
Daily Market Movement: BriaCell Therapeutics Corp (BCTX) Sees a -34.68 Decrease, Closing at 0.81 - The Dwinnex
BriaCell Therapeutics Announces $5 Million Offering - The Manila Times
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor - BioSpace
BriaCell sets price for $5 million share and warrant offering - Investing.com
BriaCell sets price for $5 million share and warrant offering By Investing.com - Investing.com Canada
BriaCell Therapeutics Launches $5 Million Offering - TipRanks
BriaCell stock dips on data for breast cancer drug (NASDAQ:BCTX) - Seeking Alpha
Briacell Reports 100% Resolution Of Brain Metastasis In Breast Cancer Patient With “Eye-Bulging” Tumor - MENAFN.COM
BriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor - Marketscreener.com
There is no way BriaCell Therapeutics Corp (BCTX) can keep these numbers up - SETE News
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with 'Eye-Bulging” Tumor - The Manila Times
Understanding the Risks of Investing in BriaCell Therapeutics Corp (BCTX) - Knox Daily
A closer look at BCTX’s price-to-free cash flow ratio - US Post News
BriaCell Therapeutics Corp’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock - Yahoo Finance
BriaCell Therapeutics Corp [BCTX] stock Initiated by H.C. Wainwright analyst, price target now $25 - The DBT News
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decline in Short Interest - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Increase in Short Interest - Defense World
A new trading data show BriaCell Therapeutics Corp (BCTX) is showing positive returns. - SETE News
BriaCell Therapeutics Corp’s latest rating changes from various analysts - Knox Daily
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):